Marius T.
- Country
- Norway
- Department
- Oncology
Research Overview
- Evaluation of BT8009 Monotherapy and BT8009 with Pembrolizumab Versus Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer
- A Randomized, Open-Label, Phase 2/3 Study of Datopotamab Deruxtecan (Dato-DXd) plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Participants with Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) who Progressed During or After Enfortumab Vedotin (EV) plus Pembrolizumab Combination Treatment. TROPION-Urothelial03 (TU03).
- IZABRIGHT-BLADDER01: A Randomized, Open-label, Phase 2/3 trial of Izalontamab Brengitecan versus platinum-based chemotherapy for metastatic urothelial cancer in participants with disease progression on or after an immunotherapy-based treatment
Data & Insights
Has run more than one trial at 55 of 176 partner sites.
Specializations
Oncology Focus
This investigator specializes in the treatment of urothelial cancer, with particular emphasis on advanced disease states including locally advanced and metastatic conditions.
- Advanced Urothelial Cancer Management
- Metastatic Disease Treatment
The investigator's work encompasses comprehensive approaches to urological malignancies.
Therapeutic Approaches
The investigator explores innovative treatment combinations including immunotherapy and targeted therapies for urological cancers.
- Combination Therapy Strategies
- Novel Treatment Protocols
Their work involves evaluating various therapeutic modalities for optimal patient outcomes.
Clinical Assessment
The investigator utilizes advanced evaluation methodologies including RECIST criteria and incorporates independent review processes in clinical assessments.
- Response Evaluation
- Disease Progression Assessment
Their expertise includes systematic evaluation of treatment efficacy in oncology.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.